What is PD Holdings?
Operating as a sophisticated Contract Development and Manufacturing Organization, PD Holdings provides critical technical services including spray drying, amorphous solid dispersions, and advanced particle engineering. By leveraging state-of-the-art facilities across the United States and the United Kingdom, the company serves a diverse clientele ranging from global pharmaceutical giants to nutraceutical innovators. Their core competency lies in improving the bioavailability of complex molecules, a vital requirement for modern drug development. Through rigorous regulatory compliance and a focus on continuous granulation and microencapsulation, PD Holdings functions as an essential partner in the pharmaceutical supply chain, ensuring that therapeutic products meet the highest standards of quality and manufacturing efficiency.
How much funding has PD Holdings raised?
PD Holdings has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in PD Holdings
PPP
Public-Private Partnership
What's next for PD Holdings?
With this major strategic investment, PD Holdings is well-positioned to expand its footprint in the global CDMO market. The company is expected to prioritize the optimization of its manufacturing facilities to meet the rising demand for functional products and Sevelamer API. Future strategic initiatives will likely focus on deepening its technical expertise in final dosage forms and scaling its capacity to support large-scale commercial projects. By integrating advanced particle engineering technologies, the firm aims to address the growing complexity of drug formulations, thereby securing its role as a preferred partner for pharmaceutical and consumer health organizations seeking to enhance product efficacy and manufacturing throughput.
See full PD Holdings company page
